Thalidomide as a multitarget drug and its application as a template for drug design

Yuichi Hashimoto, Aya Tanatani, Kazuo Nagasawa, Hiroyuki Miyachi

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

Thalidomide is a hypnotic/sedative drug which was withdrawn from the market because of teratogenicity. However, it has been established to be useful for the treatment of various diseases, including Hansen's disease and various cancers. Thalidomide elicits a wide range of pharmacological effects, including anti-cachexia, antitumor-promoting, antiangiogenic, immunosuppressing, antiviral, hypoglycemic, cell differentiation-inducing and antimetastatic activities. It appears to be a multitarget drug, and hypothetical target events/molecules of thalidomide include TNF-α production, nuclear androgen receptor, cyclooxygenases, nuclear retinoic acid receptor, aminopeptidases and α-glucosidase. Specific and potent compounds acting on each of these target phenomena/molecules have been prepared by appropriate modification of the thalidomide structure and are expected to be superior lead compounds for novel immunomodulators, antiangiogenic agents and antitumor-promoting agents.

Original languageEnglish
Pages (from-to)383-391
Number of pages9
JournalDrugs of the Future
Volume29
Issue number4
DOIs
Publication statusPublished - Apr 2004
Externally publishedYes

Fingerprint

Thalidomide
Drug Design
Pharmaceutical Preparations
Glucosidases
Cachexia
Retinoic Acid Receptors
Aminopeptidases
Angiogenesis Inhibitors
Immunologic Factors
Androgen Receptors
Leprosy
Prostaglandin-Endoperoxide Synthases
Cytoplasmic and Nuclear Receptors
Hypnotics and Sedatives
Hypoglycemic Agents
Antineoplastic Agents
Antiviral Agents
Cell Differentiation
Pharmacology
Neoplasms

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology
  • Drug Discovery

Cite this

Thalidomide as a multitarget drug and its application as a template for drug design. / Hashimoto, Yuichi; Tanatani, Aya; Nagasawa, Kazuo; Miyachi, Hiroyuki.

In: Drugs of the Future, Vol. 29, No. 4, 04.2004, p. 383-391.

Research output: Contribution to journalArticle

Hashimoto, Yuichi ; Tanatani, Aya ; Nagasawa, Kazuo ; Miyachi, Hiroyuki. / Thalidomide as a multitarget drug and its application as a template for drug design. In: Drugs of the Future. 2004 ; Vol. 29, No. 4. pp. 383-391.
@article{97b9d321c9064d7dba7312efe57ee2ef,
title = "Thalidomide as a multitarget drug and its application as a template for drug design",
abstract = "Thalidomide is a hypnotic/sedative drug which was withdrawn from the market because of teratogenicity. However, it has been established to be useful for the treatment of various diseases, including Hansen's disease and various cancers. Thalidomide elicits a wide range of pharmacological effects, including anti-cachexia, antitumor-promoting, antiangiogenic, immunosuppressing, antiviral, hypoglycemic, cell differentiation-inducing and antimetastatic activities. It appears to be a multitarget drug, and hypothetical target events/molecules of thalidomide include TNF-α production, nuclear androgen receptor, cyclooxygenases, nuclear retinoic acid receptor, aminopeptidases and α-glucosidase. Specific and potent compounds acting on each of these target phenomena/molecules have been prepared by appropriate modification of the thalidomide structure and are expected to be superior lead compounds for novel immunomodulators, antiangiogenic agents and antitumor-promoting agents.",
author = "Yuichi Hashimoto and Aya Tanatani and Kazuo Nagasawa and Hiroyuki Miyachi",
year = "2004",
month = "4",
doi = "10.1358/dof.2004.029.04.792298",
language = "English",
volume = "29",
pages = "383--391",
journal = "Drugs of the Future",
issn = "0377-8282",
publisher = "Prous Science",
number = "4",

}

TY - JOUR

T1 - Thalidomide as a multitarget drug and its application as a template for drug design

AU - Hashimoto, Yuichi

AU - Tanatani, Aya

AU - Nagasawa, Kazuo

AU - Miyachi, Hiroyuki

PY - 2004/4

Y1 - 2004/4

N2 - Thalidomide is a hypnotic/sedative drug which was withdrawn from the market because of teratogenicity. However, it has been established to be useful for the treatment of various diseases, including Hansen's disease and various cancers. Thalidomide elicits a wide range of pharmacological effects, including anti-cachexia, antitumor-promoting, antiangiogenic, immunosuppressing, antiviral, hypoglycemic, cell differentiation-inducing and antimetastatic activities. It appears to be a multitarget drug, and hypothetical target events/molecules of thalidomide include TNF-α production, nuclear androgen receptor, cyclooxygenases, nuclear retinoic acid receptor, aminopeptidases and α-glucosidase. Specific and potent compounds acting on each of these target phenomena/molecules have been prepared by appropriate modification of the thalidomide structure and are expected to be superior lead compounds for novel immunomodulators, antiangiogenic agents and antitumor-promoting agents.

AB - Thalidomide is a hypnotic/sedative drug which was withdrawn from the market because of teratogenicity. However, it has been established to be useful for the treatment of various diseases, including Hansen's disease and various cancers. Thalidomide elicits a wide range of pharmacological effects, including anti-cachexia, antitumor-promoting, antiangiogenic, immunosuppressing, antiviral, hypoglycemic, cell differentiation-inducing and antimetastatic activities. It appears to be a multitarget drug, and hypothetical target events/molecules of thalidomide include TNF-α production, nuclear androgen receptor, cyclooxygenases, nuclear retinoic acid receptor, aminopeptidases and α-glucosidase. Specific and potent compounds acting on each of these target phenomena/molecules have been prepared by appropriate modification of the thalidomide structure and are expected to be superior lead compounds for novel immunomodulators, antiangiogenic agents and antitumor-promoting agents.

UR - http://www.scopus.com/inward/record.url?scp=2642512949&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2642512949&partnerID=8YFLogxK

U2 - 10.1358/dof.2004.029.04.792298

DO - 10.1358/dof.2004.029.04.792298

M3 - Article

AN - SCOPUS:2642512949

VL - 29

SP - 383

EP - 391

JO - Drugs of the Future

JF - Drugs of the Future

SN - 0377-8282

IS - 4

ER -